Targeting Nectin-4 in Bladder Cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Metastatic urothelial carcinoma has limited treatment options.
• Platinum chemotherapy and immune checkpoint inhibitors are standard treatments.
• Enfortumab vedotin targets nectin-4, a protein often overexpressed in urothelial cancer.

Purpose of the Study:

• To evaluate the safety and efficacy of enfortumab vedotin in patients with metastatic urothelial carcinoma.
• To assess response rates in patients with prior disease progression.

Main Methods:

• Phase I clinical trial.
• Enfortumab vedotin administered as treatment.
• Patient population included those with metastatic urothelial carcinoma.

Main Results:

• Enfortumab vedotin demonstrated considerable efficacy.
• Robust responses observed in patients with disease progression on platinum chemotherapy.
• Significant responses noted in patients who progressed on immune checkpoint blockade.

Conclusions:

• Enfortumab vedotin shows significant potential as a treatment for metastatic urothelial carcinoma.
• The drug is effective even in heavily pre-treated patient populations.
• Further investigation in larger trials is warranted.